Michael Secora Sells 15,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Michael Secora also recently made the following trade(s):

• On Tuesday, October 8th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00.
• On Tuesday, September 10th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.17, for a total transaction of $92,550.00.

Recursion Pharmaceuticals Trading Down 5.6 %

Shares of NASDAQ RXRX traded down $0.41 during mid-day trading on Thursday, hitting $6.91. The stock had a trading volume of 6,567,201 shares, compared to its average volume of 5,730,846. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.89 and a 1 year high of $15.74. The business has a 50 day moving average price of $6.64 and a two-hundred day moving average price of $7.62. The firm has a market cap of $1.94 billion, a P/E ratio of -4.78 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.43) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, November 7th. Jefferies Financial Group decreased their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.25.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Axxcess Wealth Management LLC increased its position in Recursion Pharmaceuticals by 4.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after purchasing an additional 1,795 shares during the period. Green Alpha Advisors LLC increased its position in Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the period. Interchange Capital Partners LLC grew its position in shares of Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after buying an additional 2,349 shares during the period. Amalgamated Bank grew its position in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. grew its position in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after buying an additional 2,598 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.